NCT04187833View on ClinicalTrials.gov

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 5, 2020

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Metastatic or Unresectable Melanoma
Interventions
DRUG

Nivolumab

480mg intravenously every 4 weeks (28 days)

DRUG

Talazoparib

1mg orally daily

Trial Locations (1)

44195

Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Case Comprehensive Cancer Center

OTHER

NCT04187833 - Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes | Biotech Hunter | Biotech Hunter